Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Lipocine (LPCN) EBITDA (2016 - 2025)

Lipocine's EBITDA history spans 13 years, with the latest figure at -$3.2 million for Q3 2025.

  • For Q3 2025, EBITDA fell 44.64% year-over-year to -$3.2 million; the TTM value through Sep 2025 reached -$5.5 million, down 35.94%, while the annual FY2024 figure was $10231.0, 100.06% up from the prior year.
  • EBITDA reached -$3.2 million in Q3 2025 per LPCN's latest filing, down from -$2.2 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $12.6 million in Q4 2021 to a low of -$6.8 million in Q2 2021.
  • Average EBITDA over 5 years is -$1.8 million, with a median of -$2.6 million recorded in 2022.
  • Peak YoY movement for EBITDA: soared 379.48% in 2021, then crashed 176.93% in 2023.
  • A 5-year view of EBITDA shows it stood at $12.6 million in 2021, then crashed by 117.24% to -$2.2 million in 2022, then fell by 4.01% to -$2.3 million in 2023, then soared by 178.8% to $1.8 million in 2024, then tumbled by 278.57% to -$3.2 million in 2025.
  • Per Business Quant, the three most recent readings for LPCN's EBITDA are -$3.2 million (Q3 2025), -$2.2 million (Q2 2025), and -$1.9 million (Q1 2025).